Patients who experience heart attacks often have immediate ischemia and cell death, which causes a decrease in cardiac function, contributing to higher mortality and morbidity.
Researchers at Stanford University have discovered a first-in-class covalent inhibitor that binds to activated Fis1 and prevents mitochondrial fission and dysfunction.
Stanford scientists have developed a novel method to accelerate the development of T cell target probes known as Rapid Identification of Peptide-ligands from Protein Antigen (RIPPA).